American Society of Hematology. (2019).
FDA Approves Givosiran for Acute Hepatic Porphyria.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-givosiran-for-acute-hepatic-porphyria.
American Society of Hematology.
"FDA Approves Givosiran for Acute Hepatic Porphyria." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-givosiran-for-acute-hepatic-porphyria
(label-accessed May 30, 2025).
"American Society of Hematology."
FDA Approves Givosiran for Acute Hepatic Porphyria, 30 May. 2025 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-givosiran-for-acute-hepatic-porphyria.
